Payment overview · 2025
General Payments
$8,950.43
131 reported records · 29 companies
Healthcare provider profile · identity verified
James Gregory Sullivan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BIRMINGHAM, AL · NPI 1588613020
Verified facts
What the public records show
CMS Open Payments records show James Gregory Sullivan, MD received $8,950.43 in general payments during 2025 across 131 reported records.
Amgen Inc. accounted for 40.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Nurtec Odt, Ozempic, Rexulti, Rybelsus, Sublocade, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 326 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 531 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 280 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 326 claims for Linzess by this doctor in 2024.
Indivior Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SUBLOCADE as an associated drug or biological on 22829 records involving 8874 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Sublocade by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 353 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 374 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 531 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Nurtec Odt by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulance by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $3,618.44 | 40.4% | 18 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $3,192.11 | 35.7% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $314.64 | 3.5% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $264.17 | 3.0% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $176.83 | 2.0% | 8 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $173.11 | 1.9% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $150.52 | 1.7% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $127.44 | 1.4% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $101.08 | 1.1% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $100.94 | 1.1% | 5 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $90.71 | 1.0% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $87.00 | 1.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $70.84 | 0.8% | 4 | 2025 |
| AXOGEN | Unresolved — no canonical attribution shown | $63.37 | 0.7% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $54.20 | 0.6% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $49.60 | 0.6% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $49.30 | 0.6% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $38.88 | 0.4% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $31.64 | 0.3% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $28.43 | 0.3% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $24.21 | 0.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.22 | 0.2% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $20.93 | 0.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.91 | 0.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.68 | 0.2% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $16.60 | 0.2% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $16.45 | 0.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.94 | 0.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.24 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,250.00 | 4 |
| Food and Beverage | $2,916.49 | 124 |
| Travel and Lodging | $783.94 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $3,594.39 | 17 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $3,192.11 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $235.73 | 13 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $218.70 | 12 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $192.77 | 9 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $173.11 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $162.44 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $162.40 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $150.52 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $101.08 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $100.94 | 5 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $90.71 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $87.10 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $87.00 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $80.10 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $71.06 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $56.38 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $54.20 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $53.64 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $52.00 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $49.30 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $38.88 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.88 | 3 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $32.25 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $31.64 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $29.40 | 1 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $28.43 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $24.21 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.22 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $20.93 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 531 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 72 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 165 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 326 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 353 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 53 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 374 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 106 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 64 | exact normalized | Medicare Part D |
| SUBLOCADE sublocade |
2025 | Sublocade | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 280 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
326 | 76 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
72 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
64 | 16 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
531 | 85 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
280 | 62 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
326 | 76 |
| Indivior Inc. Exact reporting entity; no affiliate inference |
2025 | SUBLOCADE open payments reported associated product |
CMS Open Payments — General Payments 22829 supporting records · 8874 recipient NPIs · example record 1240470773 |
Sublocade · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
165 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
353 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
102 | 18 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
106 | 30 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
374 | 76 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
64 | 13 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
106 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
531 | 85 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 2431 | 252 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1883 | 277 |
| Gabapentin | Gabapentin | 1622 | 263 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1434 | 374 |
| Alprazolam | Alprazolam | 1292 | 147 |
| Buprenorphine Hcl | Buprenorphine Hcl | 1158 | 147 |
| Clonazepam | Clonazepam | 1151 | 131 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1036 | 279 |
| Famotidine | Famotidine | 1004 | 279 |
| Levothyroxine Sodium | Levothyroxine Sodium | 888 | 225 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 771 | 184 |
| Tramadol Hcl | Tramadol Hcl | 724 | 125 |
| Ondansetron Hcl | Ondansetron Hcl | 716 | 125 |
| Quetiapine Fumarate | Quetiapine Fumarate | 667 | 126 |
| Trazodone Hcl | Trazodone Hcl | 631 | 148 |
| Tizanidine Hcl | Tizanidine Hcl | 630 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 551 | 149 |
| Ibuprofen | Ibuprofen | 541 | 103 |
| Eliquis | Apixaban | 531 | 85 |
| Potassium Chloride | Potassium Chloride | 498 | 117 |
| Methocarbamol | Methocarbamol | 492 | 122 |
| Omeprazole | Omeprazole | 484 | 123 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 482 | 140 |
| Furosemide | Furosemide | 479 | 136 |
| Metformin Hcl | Metformin Hcl | 458 | 116 |
| Tamsulosin Hcl | Tamsulosin Hcl | 422 | 104 |
| Zolpidem Tartrate | Zolpidem Tartrate | 412 | 61 |
| Lisinopril | Lisinopril | 401 | 115 |
| Pregabalin | Pregabalin | 389 | 60 |
| Amoxicillin | Amoxicillin | 388 | 243 |
| Fluoxetine Hcl | Fluoxetine Hcl | 384 | 92 |
| Promethazine Hcl | Promethazine Hcl | 377 | 86 |
| Clonidine Hcl | Clonidine Hcl | 375 | 83 |
| Ozempic | Semaglutide | 374 | 76 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 366 | 75 |
| Ezetimibe | Ezetimibe | 364 | 109 |
| Mounjaro | Tirzepatide | 353 | 51 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 345 | 89 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 335 | 89 |
| Diclofenac Sodium | Diclofenac Sodium | 331 | 92 |
| Diazepam | Diazepam | 326 | 34 |
| Linzess | Linaclotide | 326 | 76 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 323 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 322 | 95 |
| Carvedilol | Carvedilol | 318 | 79 |
| Doxycycline Hyclate | Doxycycline Hyclate | 303 | 209 |
| Metoprolol Succinate | Metoprolol Succinate | 296 | 79 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 280 | 62 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 277 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 267 | 65 |
| Nebivolol Hcl | Nebivolol Hcl | 266 | 78 |
| Fluconazole | Fluconazole | 265 | 97 |
| Sucralfate | Sucralfate | 261 | 79 |
| Montelukast Sodium | Montelukast Sodium | 249 | 58 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 246 | 97 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 239 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 237 | 55 |
| Lovastatin | Lovastatin | 227 | 54 |
| Methylprednisolone | Methylprednisolone | 226 | 139 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 220 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 219 | 65 |
| Allopurinol | Allopurinol | 217 | 70 |
| Meloxicam | Meloxicam | 214 | 68 |
| Pravastatin Sodium | Pravastatin Sodium | 214 | 57 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 201 | 59 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 198 | 47 |
| Atenolol | Atenolol | 187 | 44 |
| Metoclopramide Hcl | Metoclopramide Hcl | 186 | 45 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 180 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 175 | 53 |
| Modafinil | Modafinil | 174 | 27 |
| Risperidone | Risperidone | 170 | 33 |
| Azithromycin | Azithromycin | 169 | 131 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 168 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 165 | 41 |
| Jardiance | Empagliflozin | 165 | 35 |
| Levetiracetam | Levetiracetam | 162 | 32 |
| Lorazepam | Lorazepam | 162 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 160 | 43 |
| Olanzapine | Olanzapine | 157 | 39 |
| Simvastatin | Simvastatin | 154 | 39 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 150 | 102 |
| Losartan Potassium | Losartan Potassium | 149 | 46 |
| Aripiprazole | Aripiprazole | 147 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 36 |
| Mirtazapine | Mirtazapine | 142 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 42 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 140 | 35 |
| Sertraline Hcl | Sertraline Hcl | 139 | 35 |
| Baclofen | Baclofen | 137 | 31 |
| Testosterone Cypionate | Testosterone Cypionate | 133 | 41 |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 131 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 130 | 34 |
| Amitriptyline Hcl | Amitriptyline Hcl | 128 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 128 | 31 |
| Prednisone | Prednisone | 124 | 49 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 123 | 32 |
| Celecoxib | Celecoxib | 120 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 120 | 19 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 119 | 36 |
| Buspirone Hcl | Buspirone Hcl | 118 | 29 |
| Estradiol | Estradiol | 116 | 31 |
| Methylphenidate Hcl | Methylphenidate Hcl | 115 | 22 |
| Lidocaine | Lidocaine | 113 | 28 |
| Mupirocin | Mupirocin | 110 | 68 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 109 | 30 |
| Bupropion Xl | Bupropion Hcl | 107 | 30 |
| Rexulti | Brexpiprazole | 106 | 30 |
| Temazepam | Temazepam | 106 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 105 | 29 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 104 | 23 |
| Lamotrigine | Lamotrigine | 104 | 20 |
| Trulicity | Dulaglutide | 102 | 18 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 97 | 19 |
| Cephalexin | Cephalexin | 97 | 65 |
| Propranolol Hcl Er | Propranolol Hcl | 96 | 23 |
| Raloxifene Hcl | Raloxifene Hcl | 96 | 24 |
| Scopolamine | Scopolamine | 96 | 25 |
| Alendronate Sodium | Alendronate Sodium | 93 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 91 | 14 |
| Metformin Hcl Er | Metformin Hcl | 90 | 34 |
| Ranolazine Er | Ranolazine | 90 | 33 |
| Topiramate | Topiramate | 90 | 22 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 85 | 17 |
| Nabumetone | Nabumetone | 85 | 23 |
| Spironolactone | Spironolactone | 84 | 29 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 82 | 24 |
| Donepezil Hcl | Donepezil Hcl | 81 | 19 |
| Glimepiride | Glimepiride | 81 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 81 | 21 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 80 | 19 |
| Nitroglycerin | Nitroglycerin | 79 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 17 |
| Ondansetron Odt | Ondansetron | 77 | 19 |
| Chlorthalidone | Chlorthalidone | 75 | 20 |
| Warfarin Sodium | Warfarin Sodium | 75 | suppressed |
| Eszopiclone | Eszopiclone | 74 | 14 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 74 | 13 |
| Farxiga | Dapagliflozin Propanediol | 72 | 14 |
| Xarelto | Rivaroxaban | 72 | 19 |
| Colchicine | Colchicine | 71 | 23 |
| Myrbetriq | Mirabegron | 71 | 16 |
| Propranolol Hcl | Propranolol Hcl | 71 | 26 |
| Clobetasol Propionate | Clobetasol Propionate | 69 | 21 |
| Nortriptyline Hcl | Nortriptyline Hcl | 67 | suppressed |
| Rybelsus | Semaglutide | 64 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 64 | 16 |
| Carbamazepine | Carbamazepine | 63 | 15 |
| Liothyronine Sodium | Liothyronine Sodium | 63 | 18 |
| Entresto | Sacubitril/Valsartan | 61 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 60 | 12 |
| Meclizine Hcl | Meclizine Hcl | 59 | 21 |
| Metronidazole | Metronidazole | 59 | 29 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 58 | 18 |
| Ursodiol | Ursodiol | 58 | 19 |
| Minoxidil | Minoxidil | 57 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | 19 |
| Valacyclovir | Valacyclovir Hcl | 56 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 15 |
| Felodipine Er | Felodipine | 55 | suppressed |
| Nifedipine Er | Nifedipine | 53 | 11 |
| Nurtec Odt | Rimegepant Sulfate | 53 | 13 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 52 | 16 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 51 | suppressed |
| Finasteride | Finasteride | 51 | 16 |
| Gentamicin Sulfate | Gentamicin Sulfate | 50 | 19 |
| Hydrocortisone | Hydrocortisone | 50 | 17 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 50 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 49 | suppressed |
| Acyclovir | Acyclovir | 49 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 48 | 11 |
| Phenobarbital | Phenobarbital | 48 | 12 |
| Repatha Sureclick | Evolocumab | 48 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 47 | 15 |
| Vyvanse | Lisdexamfetamine Dimesylate | 47 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 45 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 44 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 44 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 14 |
| Nystatin | Nystatin | 42 | 24 |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 42 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 41 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 40 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 39 | suppressed |
| Edarbi | Azilsartan Medoxomil | 39 | suppressed |
| Naproxen | Naproxen | 39 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 39 | suppressed |
| Victoza 3-Pak | Liraglutide | 39 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 37 | 11 |
| Spiriva Handihaler | Tiotropium Bromide | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 36 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 36 | 13 |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Repatha Syringe | Evolocumab | 35 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 34 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Lubiprostone | Lubiprostone | 33 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 33 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 33 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 31 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 30 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 30 | 14 |
| Latanoprost | Latanoprost | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | 12 |
| Sublocade | Buprenorphine | 30 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 29 | suppressed |
| Testosterone | Testosterone | 29 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 29 | 20 |
| Vraylar | Cariprazine Hcl | 28 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 27 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 27 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 27 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 27 | suppressed |
| Armodafinil | Armodafinil | 26 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Ibu | Ibuprofen | 25 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 24 | suppressed |
| Roflumilast | Roflumilast | 24 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Valproic Acid | Valproic Acid | 23 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 11 |
| Pentoxifylline | Pentoxifylline | 21 | suppressed |
| Triazolam | Triazolam | 21 | suppressed |
| Trulance | Plecanatide | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Ssd | Silver Sulfadiazine | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Novolog | Insulin Aspart | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 17 | suppressed |
| Letrozole | Letrozole | 17 | suppressed |
| Misoprostol | Misoprostol | 17 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Ivermectin | Ivermectin | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Sumatriptan | Sumatriptan | 15 | suppressed |
| Ultiguard Safepack-Pen Needle | Pen Needle, Diabetic,disp Unit | 15 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 14 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Humira Pen | Adalimumab | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 14 | suppressed |
| Permethrin | Permethrin | 14 | suppressed |
| Teriparatide | Teriparatide | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Veozah | Fezolinetant | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Dotti | Estradiol | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Itraconazole | Itraconazole | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Captopril | Captopril | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Olanzapine Odt | Olanzapine | 11 | suppressed |
| Olanzapine-Fluoxetine Hcl | Olanzapine/Fluoxetine Hcl | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $8,950.43 · 131 records | Amgen Inc. | AIRSUPRA, APLENZIN, BRIXADI, CREON, Cologuard Collection Kit, ELIQUIS, FANAPT, FARXIGA, IBSRELA, INGREZZA, JARDIANCE, KRYSTEXXA, Kerendia, LEQVIO, LINZESS, LOREEV XR, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, SUBLOCADE, Sunosi, Symbravo, TRELEGY ELLIPTA, TRINTELLIX, Tymlos, VIBERZI, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZTLido | 24 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error